مقایسهٔ روش‌ها

	مقیاس آنالوگ بصری خارش (Pruritus VAS)	POEM (Patient-Oriented Eczema Measure)	شاخص SCORAD (امتیازدهی درماتیت آتوپیک)
حوزه	پوست	پوست	پوست
خانواده	Process / pipeline	Process / pipeline	Process / pipeline
سال پیدایش	1983 (VAS); widely adopted for pruritus 1990s–2000s	2004	1993
پدیدآور	Huskisson EC (VAS methodology); adapted for pruritus in dermatology	Charman CR, Venn AJ, Williams HC	European Task Force on Atopic Dermatitis (ETFAD)
نوع	Self-report	Self-report	Clinician-rated
منبع بنیادین	Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587-593.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.	Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19.
نام‌های دیگر	Itch VAS, Pruritus Severity Scale	POEM Score	SCORAD Index
مرتبط	3	2	3
خلاصه	The Pruritus Visual Analog Scale (VAS) is a simple, single-item patient-administered tool measuring itch intensity on a continuous 0–10 (or 0–100) scale. Adapted from the original VAS for pain, it is one of the most frequently used outcome measures in dermatological research and clinical practice due to its simplicity, brevity, and responsiveness to treatment. Pruritus VAS is essential in trials of antipruritic therapies and in conditions where itching is a primary complaint (atopic dermatitis, psoriasis, pruritus ani, lichen planus).	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.	The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.